Gene · 9760
Papers2,030
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
441 to 460 of 2,030
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Investigation of Single-Event Upset in Graphene Nano-Ribbon FET SRAM Cell. | Micromachines (Basel) | 2023 | 37512760 | PubTator, text mining | PubMed |
| Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma. | Int J Mol Sci | 2023 | 37511558 | PubTator, text mining | PubMed |
| Dissecting the Protective Effect of CD8+ T Cells in Response to SARS-CoV-2 mRNA Vaccination and the Potential Link with Lymph Node CD8+ T Cells. | Biology (Basel) | 2023 | 37508464 | PubTator, text mining | PubMed |
| Single-Cell Atlas Reveals the Hemocyte Subpopulations and Stress Responses in Asian Giant Softshell Turtle during Hibernation. | Biology (Basel) | 2023 | 37508424 | PubTator, text mining | PubMed |
| A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance. | Clin Cancer Res | 2023 | 37505479 | PubTator, text mining | PubMed |
| Serum soluble immune checkpoint levels predict cervical lymph node metastasis of differentiated thyroid carcinoma patients. | Cancer Med | 2023 | 37501393 | PubTator, text mining | PubMed |
| Protein target highlights in CASP15: Analysis of models by structure providers. | Proteins | 2023 | 37493353 | PubTator, text mining | PubMed |
| Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial. | Nat Med | 2023 | 37488287 | PubTator, text mining | PubMed |
| Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma. | Cancer Res Commun | 2023 | 37484198 | PubTator, text mining | PubMed |
| Single-Cell Characterization of Pulmonary Nodules Implicates Suppression of Immunosurveillance across Early Stages of Lung Adenocarcinoma. | Cancer Res | 2023 | 37477508 | PubTator, text mining | PubMed |
| TOX2 coordinates with TET2 to positively regulate central memory differentiation in human CAR T cells. | Sci Adv | 2023 | 37467321 | PubTator, text mining | PubMed |
Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study. | BMC Cancer | 2023 | 37464378 | PubTator, text mining | PubMed |
| Intratumoral immune triads are required for adoptive T cell therapy-mediated elimination of solid tumors. | bioRxiv | 2023 | 37461721 | PubTator, text mining | PubMed |
| CD26lowPD-1+ CD8 T cells are terminally exhausted and associated with leukemia progression in acute myeloid leukemia. | Front Immunol | 2023 | 37457737 | PubTator, text mining | PubMed |
| Remodeling the tumor microenvironment to overcome treatment resistance in HPV-negative head and neck cancer. | Cancer Drug Resist | 2023 | 37457128 | PubTator, text mining | PubMed |
| [The expression and correlation analysis of TOX and inhibitory receptors on peripheral blood CD8+T cells in patients with aplastic anemia]. | Zhonghua Yi Xue Za Zhi | 2023 | 37455127 | PubTator, text mining | PubMed |
| Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome. | Leukemia | 2023 | 37452103 | PubTator, text mining | PubMed |
| Infiltration of a Unique CD8+CD274+ Cell Subgroup in Hepatocellular Carcinoma is Associated with Poor Clinical Outcomes. | J Hepatocell Carcinoma | 2023 | 37449280 | PubTator, text mining | PubMed |
| Inhibitory IL-10-producing CD4+ T cells are T-bet-dependent and facilitate cytomegalovirus persistence via coexpression of arginase-1. | Elife | 2023 | 37440306 | PubTator, text mining | PubMed |
| Pathology and new insights in central nervous system lymphomas. | Curr Opin Oncol | 2023 | 37439536 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9760/papers?page=23